LIPS study (Lanreotide In Polycystic kidney disease Study) is a prospective randomized double
blind placebo controlled study. The main objective is to prove that lanreotide, a
somatostatin analog, is able to reduce the glomerular filtration rate decline over 3 years by
at least 30%. Cardiovascular outcomes, blood pressure, quality of life and safety are among
the secondary outcomes. The study, which will include 180 ADPKD patients, is scheduled to
start in early 2014.
An equal number of patients with chronic kidney disease stage 2 (90 patients with GFR 89 to
60 ml/mn/1.73 m2) and chronic kidney disease stage 3 (90 patients with GFR 59 to 30
ml/mn/1.73 m2) will be included. The primary endpoint (GFR decline) will be assessed by
repeated measures, in the overall population as well as in the two GFR stratus.
Phase:
Phase 3
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborator:
IPSEN pharmaceutical company, Boulogne-Billancourt, France